news
Press release
 
October 5, 2015
Leading Interventional Cardiologists to Discuss CorPath® System's Role in Physician Radiation Reduction and Procedural Precision in Complex and Radial PCI at TCT 2015

Corindus Vascular Robotics to showcase capabilities of CorPath System

Waltham, MA – October 5, 2015Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS] announced today that renowned interventional cardiologists will highlight their use of the CorPath System through presentations and poster sessions during the upcoming TCT2015 meeting, Oct. 11-15, in San Francisco. Physicians will present their experience using the CorPath System during PCI procedures to demonstrate the radiation reduction that it provides.

Corindus Vascular Robotics, Inc. will showcase the System's capabilities during complex PCI procedures and highlight recent studies pertaining to occupational hazards and robotic precision at booth #1525.

Presentations as part of the scientific program include:

  • "Cath Lab Technology Evolution: Robotics, Imaging Integration, and Radiation Reduction/Featured Technological Trends 2: Robotically Assisted Vascular Procedures," Dr. Ehtisham Mahmud, UC San Diego, Monday, Oct. 12, 8:10 a.m. Moscone West, 2nd Floor, Room 2014 – 2018.
  • "Initial Clinical Experience Performing Robotic Percutaneous Coronary Intervention from the Radial Approach,"* Dr. Joseph Sheets, Spectrum Healthcare, Thursday, Oct. 15, 12:30 p.m. Moscone South, Lower Level, Room 104.

Abstract poster sessions include:

  • "Feasibility and Success of Radial-Access Robotic Percutaneous Coronary Intervention: Insights From The PRECISION Registry,"* featuring the findings of Drs. Ryan Madder, Paul T. Campbell, Ronald Caputo, Vijaykumar Kasi, Ehtisham Mahmud, J. Jeffery Marshall, Tomasz Stys and Giora Weisz.
  • "RAPID (Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease) Study*,"* featuring the findings of Drs. Ehtisham Mahmud, Florian Schmid, Peter Kalmar, Hannes Duetschmann and Marianne Brodmann.
  • "Longitudinal Geographic Miss (LGM) in Robotic-Assisted versus Manual Percutaneous Coronary Interventions," featuring the findings of Drs. Emile Mehanna, Hiram Bezerra, Christopher Metzger, Ronald Caputo, Juan F Granada, George W. Vetrovec and Giora Weisz.
  • "Feasibility of Robotic Percutaneous Coronary Intervention for Unprotected Left Main Stenosis in the Presence and Absence of Left Ventricular Hemodynamic Support with Impella," featuring the findings of Drs. Ehtisham Mahmud, Arturo Dominguez, John Bahadorani, Mitul Patel and Ryan Reeves.
  • "Robotically Assisted Unprotected Left Main PCI with Impella Support," featuring the findings of Drs. John Bahadorani, Ehtisham Mahmud, and Arturo Domingues.

All poster sessions occur on Tuesday, Oct. 14, 4-6 p.m.

"Robotic technology is changing the way we perform PCIs in the cath lab by enabling enhanced visualization and precision while offering enhanced radiation protection, which is especially important as procedures become longer and more complex," said Dr. Mahmud, Chief of Cardiovascular Medicine, Director of Sulpizio Cardiovascular Center-Medicine, and Director of Interventional Cardiology at UC San Diego Health System. "TCT provides an ideal venue for those of us who have adopted the technology to share our experiences with other interventionalists."

"The peer to peer education of advanced robotic complex PCI at TCT is an important step in the process of clinical expansion and awareness of the CorPath System's capabilities. We are looking forward to a very productive conference as we provide the best procedure solution for the growing concern of occupational hazards in the cath lab," said David Handler, President and CEO of Corindus. "Use of the CorPath System in the cath lab continues to grow and our users continue to successfully use robotic-assistance to treat patients during complex PCI procedures."

The CorPath System is the first FDA-approved medical device to bring robotic precision and accuracy to help optimize clinical outcomes during coronary angioplasties. Additionally, the CorPath System reduces radiation exposure for the interventional cardiologist by approximately 95%, according to the 2012 PRECISE Study.**

TCT Meeting attendees can register here to schedule a demo of complex robotic-assisted PCI with the CorPath System at the Corindus Vascular Robotics Booth #1525.

* CorPath is intended for use in the remote delivery and manipulation of coronary guidewires and balloon/stent catheters during PCI procedures.

**PRECISE Study was sponsored by Corindus, Inc.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window